Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.38 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.38 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.34 |
| ▸ | SLC43A1 | O75387 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18510829 | 0.90 | LGALS9 (0.38) | GAAALDH1A1LGALS9LGALS1LGALS3 | |
| SCHEMBL16576338 | 0.88 | ALDH1A1 (0.50) | GAAALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL15304485 | 0.88 | ALDH1A1 (0.50) | GAAALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL12482663 | 0.88 | ALDH1A1 (0.50) | GAAALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL930473 | 0.88 | ALDH1A1 (0.50) | GAAALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL24371811 | 0.88 | ALDH1A1 (0.50) | GAAALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL13021363 | 0.88 | ALDH1A1 (0.50) | GAAALDH1A1LMNAKMT2AMAPT | |
| SCHEMBL14769876 | 0.87 | LMNA (0.40) | GAAALDH1A1LGALS9LGALS1LGALS3 | |
| SCHEMBL14172902 | 0.87 | GAA (0.40) | GAAALDH1A1LGALS9LGALS1LGALS3 | |
| SCHEMBL17403981 | 0.86 | GAA (0.39) | GAAALDH1A1LGALS9LGALS1LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403863-B2 | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections | IDENIX PHARMACEUTICALS LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20130064794-A1 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | IDENIX PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130064794-A1 | Substituted Carbonyloxymethylphosphoramidate Compounds and Pharmaceutical Compositions for the Treatment of Viral Infections | PYGL, HAVCR2, PNP | GAA 141/4885ALDH1A1 1186/4885LGALS9 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.